A panel of three judges U.S. Circuit Court of Appeals for the Fifth Circuit dominated this abortion capsule mifepristone can remain on the market, but with limitations that make access significantly more difficult.
The verdict provides the Supreme Court Act is poised to resolve another major abortion case following the overturning of the Roe v Wade verdict in 2022.
Wednesday's decision is on hold pending the Supreme Court's decision decides whether or not to take on the case, which means that the drug's availability is currently unchanged.
“Mifepristone is commonly used in the US to terminate pregnancy within the first 10 weeks of pregnancy,” The Hill said Nathaniel Weixel And Zach Schoenfeld previously reported. “About half of all abortions nationwide are performed using mifepristone as the first two-pill regimen. It is typically used to help manage miscarriages.”
The Court of Appeal refused to have the verdict overturned by a lower court Administration for meals and medication(FDA) Authentic Mifepristone Approval. Still, the panel upheld the lower court's decision to thwart FDA attempts over the past eight years to make the drug more accessible.
These trials recently included the FDA allowing patients to receive mifepristone in the mail and making the drug available from 10 weeks gestation only seven weeks as originally assumed.